Department of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Applied Science Private University, Amman, Jordan.
Res Social Adm Pharm. 2020 May;16(5):689-698. doi: 10.1016/j.sapharm.2019.08.027. Epub 2019 Aug 9.
Polycystic ovary syndrome (PCOS) is a serious health problem. In women experiencing PCOS, there are myriad physical and mental health consequences; anxiety/depression are commonly associated with this condition. Community pharmacists are in a pivotal position to identify and help women diagnosed with PCOS.
To investigate the prevalence/severity of anxiety/depression among females diagnosed with PCOS living in Syria (a war-zone country) and Jordan (a non-war zone country). Secondly, to evaluate the impact of a pharmaceutical care service delivered by a clinical pharmacist on participants' anxiety/depression severity.
Females, diagnosed with PCOS above the age of 16, were recruited into the study and randomly allocated into either the active or the control group. The active group participants received a PCOS pharmaceutical care service. This service involved the provision of verbal and written educational materials, with a special focus on diet and exercise. The control group participants received only standard counseling. Both groups were followed up for four months. All participants completed the Beck Anxiety Inventory and the Beck Depression Inventory at baseline and follow-up.
Data from study participants (n = 118) from both Syria (n = 60) and Jordan (n = 58) highlighted a high prevalence of anxiety (Syria = 95% vs. Jordan = 98%) and depression (Syria = 83% vs. Jordan = 65%). At follow-up, active group participants, from both countries, showed significant improvements in anxiety and depression mean scores (anxiety: Syria = 34.97 ± 14.8 vs. 30.47 ± 14.3, p < 0.001; Jordan = 26.93 ± 13.7 vs. 23.37 ± 15.2, p < 0.001; depression: Syria = 26.53 ± 12.6 vs. 22.93 ± 12.2, p < 0.001; Jordan = 17.70 ± 11.0 vs. 15.76 ± 11.1, p = 0.049). No significant improvements were evident for control group participants from either countries.
Prevalence of anxiety/depression for females with PCOS living in Syria and in Jordan is high and calls for special attention by healthcare specialists and policymakers in both countries. Females, who received the PCOS pharmaceutical care service, showed significant improvements in anxiety/depression scores. Improvements were similar in both countries.
多囊卵巢综合征(PCOS)是一个严重的健康问题。患有 PCOS 的女性会出现各种身心健康后果;焦虑/抑郁通常与这种情况有关。社区药剂师处于识别和帮助被诊断患有 PCOS 的女性的关键位置。
调查生活在叙利亚(战区国家)和约旦(非战区国家)的被诊断患有 PCOS 的女性中焦虑/抑郁的患病率/严重程度。其次,评估临床药剂师提供的药物治疗服务对参与者焦虑/抑郁严重程度的影响。
招募年龄在 16 岁以上的被诊断患有 PCOS 的女性参加研究,并将其随机分配到活性组或对照组。活性组参与者接受 PCOS 药物治疗服务。该服务包括提供口头和书面教育材料,特别侧重于饮食和运动。对照组参与者仅接受标准咨询。两组均随访四个月。所有参与者在基线和随访时均完成贝克焦虑量表和贝克抑郁量表。
来自叙利亚(n=60)和约旦(n=58)的研究参与者(n=118)的数据突出显示,焦虑(叙利亚=95% vs. 约旦=98%)和抑郁(叙利亚=83% vs. 约旦=65%)的患病率很高。随访时,来自两国的活性组参与者的焦虑和抑郁平均评分均有显著改善(焦虑:叙利亚=34.97±14.8 vs. 30.47±14.3,p<0.001;约旦=26.93±13.7 vs. 23.37±15.2,p<0.001;抑郁:叙利亚=26.53±12.6 vs. 22.93±12.2,p<0.001;约旦=17.70±11.0 vs. 15.76±11.1,p=0.049)。来自两国的对照组参与者均未显示出显著改善。
生活在叙利亚和约旦的患有 PCOS 的女性中焦虑/抑郁的患病率很高,需要两国的医疗保健专家和政策制定者特别关注。接受 PCOS 药物治疗服务的女性的焦虑/抑郁评分有显著改善。两国的改善情况相似。